Pfizer's Bold Move: Acquiring Metsera for $7.3 Billion
Pfizer has announced its acquisition of weight-loss drug developer Metsera in a deal potentially worth $7.3 billion. This move aims to enhance Pfizer's foothold in the growing obesity treatment market. The acquisition follows Pfizer's challenges with its own weight-loss developments and positions it favorably for future obesity therapies.
Pfizer has taken a significant step to secure its place in the competitive obesity treatment market with its announcement on Monday that it will acquire Metsera, a weight-loss drug developer, in a transaction valued at up to $7.3 billion. This deal includes potential future payments and marks a strategic expansion for Pfizer.
The global obesity drug market, expected to hit $150 billion by the 2030s, continues to flourish, largely attributed to the success of GLP-1-targeting therapies developed by firms like Novo Nordisk and Eli Lilly. These companies actively compete for market leadership, and drugmakers are working on next-generation therapies targeting additional hormones for effective obesity solutions.
Pfizer CEO Albert Bourla stated that acquiring Metsera propels the company into a significant therapeutic realm, leveraging Pfizer's global reach and cardiometabolic expertise to advance next-generation obesity drugs. This acquisition follows Pfizer's setbacks with its weight-loss pill danuglipron, yet analysts like Evan Seigerman see it positioning Pfizer with a strong, differentiated obesity drug pipeline.
(With inputs from agencies.)
Google News